Clinical Trial
doi: 10.1016/s0041-1345(98)01529-2.
Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups
Affiliations
- PMID: 10083102
- DOI: 10.1016/s0041-1345(98)01529-2
Item in Clipboard
Clinical Trial
Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups
Transplant Proc.
1999 Feb-Mar.
No abstract available
Similar articles
-
Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.Drugs. 1999 Dec;58(6):1029-42. doi: 10.2165/00003495-199958060-00006. Drugs. 1999. PMID: 10651389 Review.
-
Effect of daclizumab (zenapax) on prevention of acute rejection of renal transplantation.Transplant Proc. 2003 Nov;35(7):2735-6. doi: 10.1016/j.transproceed.2003.08.065. Transplant Proc. 2003. PMID: 14612098 Clinical Trial. No abstract available.
-
Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.Transplantation. 2001 Sep 15;72(5):839-45. doi: 10.1097/00007890-200109150-00017. Transplantation. 2001. PMID: 11571447 Clinical Trial.
-
Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function.Transplantation. 2001 Aug 27;72(4):642-7. doi: 10.1097/00007890-200108270-00014. Transplantation. 2001. PMID: 11544424
-
The role of newer monoclonal antibodies in renal transplantation.Transplant Proc. 2001 Feb-Mar;33(1-2):1000-1. doi: 10.1016/s0041-1345(00)02303-4. Transplant Proc. 2001. PMID: 11267163 Review. No abstract available.
Cited by
-
Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.Drugs. 1999 Dec;58(6):1029-42. doi: 10.2165/00003495-199958060-00006. Drugs. 1999. PMID: 10651389 Review.
-
Treatment of ocular inflammation in children.Paediatr Drugs. 2004;6(5):289-301. doi: 10.2165/00148581-200406050-00003. Paediatr Drugs. 2004. PMID: 15449968 Review.
-
Interleukin 2 receptor antagonists for kidney transplant recipients.Cochrane Database Syst Rev. 2010 Jan 20;2010(1):CD003897. doi: 10.1002/14651858.CD003897.pub3. Cochrane Database Syst Rev. 2010. PMID: 20091551 Free PMC article.
-
Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeys.Clin Exp Immunol. 2001 Apr;124(1):134-41. doi: 10.1046/j.1365-2249.2001.01487.x. Clin Exp Immunol. 2001. PMID: 11359452 Free PMC article.
-
Efficacy of anti-interleukin-2 receptor antibody (daclizumab) in reducing the incidence of acute rejection after renal transplantation.Nephrourol Mon. 2012 Spring;4(2):475-7. doi: 10.5812/numonthly.1806. Epub 2012 Mar 1. Nephrourol Mon. 2012. PMID: 23573470 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
